BACKGROUND: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19. METHODS: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. DISCUSSION: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review. TRIAL REGISTRATION: PROSPERO 2020 CRD42020175648.
2046-4053Geisler, Benjamin POrcid: 0000-0003-1704-6067Zahabi, LaraLang, Adam EdwardEastwood, NaomiTennant, ElaineLukic, LjiljanaSharon, EladChuang, Hai-HuaKang, Chang-BermClayton-Johnson, KnakitaAljaberi, AhmedYu, HainingBui, ChinhLe Mau, TuanLi, Wen-ChengTeodorescu, DebbieHinske, Ludwig ChristianSun, Dennis LManian, Farrin ADunn, Adam G01ZZ1603[A-D]/Bundesministerium für Bildung und Forschung/01ZZ1804[A-I]/Bundesministerium für Bildung und Forschung/Journal ArticleResearch Support, Non-U.S. Gov'tSyst Rev. 2021 May 7;10(1):143. doi: 10.1186/s13643-021-01693-7.